PPARδ Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities

The prevalence of obesity in the USA and worldwide has reached epidemic proportions during the last two decades. Drugs currently available for the treatment of obesity provide no more than 5% placebo-adjusted weight loss and are associated with undesirable side effects. Peroxisome proliferator-activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Perreault, Mylène, Erbe, David V., Tobin, James F.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2008
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577153/
https://www.ncbi.nlm.nih.gov/pubmed/18989368
http://dx.doi.org/10.1155/2008/125387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577153/
https://www.ncbi.nlm.nih.gov/pubmed/18989368
http://dx.doi.org/10.1155/2008/125387

Ejemplares similares